Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-17
2011-05-17
Loewe, Sun Jae Y. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S362100
Reexamination Certificate
active
07943651
ABSTRACT:
The present invention provides compounds of formula (I):pharmaceutical compositions comprising the compounds and the use of the compounds for the manufacture of a medicament, particularly for the treatment of inflammation and/or allergic conditions.
REFERENCES:
patent: 4837235 (1989-06-01), Bernstein et al.
patent: 6124334 (2000-09-01), Hutchinson
patent: 6245804 (2001-06-01), Lehmann et al.
patent: 6323199 (2001-11-01), Lehmann et al.
patent: 6344454 (2002-02-01), Lehmann et al.
patent: 6548534 (2003-04-01), Lehmann et al.
patent: 6897224 (2005-05-01), Jaroch et al.
patent: 2005/0131226 (2005-06-01), Rehwinkel et al.
patent: 2005/0171109 (2005-08-01), Rehwinkel et al.
patent: 2005/0209324 (2005-09-01), Rehwinkel et al.
patent: 2005/0222154 (2005-10-01), Rehwinkel et al.
patent: 2005/0234250 (2005-10-01), Lee
patent: 2005/0272823 (2005-12-01), Rehwinkel et al.
patent: 540009 (1995-08-01), None
patent: 98/54159 (1998-06-01), None
patent: 00/32584 (1998-11-01), None
patent: 03/082280 (2003-10-01), None
patent: 03/082787 (2003-10-01), None
patent: 03/082827 (2003-10-01), None
patent: 03/101932 (2003-12-01), None
patent: 03/104195 (2003-12-01), None
patent: 2005/040145 (2004-05-01), None
patent: 2004/063163 (2004-07-01), None
patent: 2005/003098 (2005-01-01), None
patent: 2005/030213 (2005-04-01), None
patent: 2005/034939 (2005-04-01), None
patent: 2005/035518 (2005-04-01), None
patent: 2005/037811 (2005-04-01), None
patent: 2005/095401 (2005-10-01), None
patent: 2006/108699 (2006-10-01), None
Chawla et al., “Challenges in Polymorphism of Pharmaceuticals”, CRIPS vol. 5, No. 1, Jan.-Mar. 2004 (4 Pages).
Newman et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products”, DDT vol. 8, No. 19, Oct. 2003, p. 898-905.
Brittain et al. #2 “Effects of pharmaceutical processing on drug polymorphs and solvates” in Polymorphism in Pharmaceutical Solids, vol. 95, p. 331-361.
Epress-Pharma-Online (http://www.expresspharmaonline.com/20031023/edit02.shtml).
Hacks Chemical Dictionary, Fourth Edition, Julius Grant, 1972, p. 203.
A. Ray et al; Anti-inflammation: direct physical association and functional antagonism between transcription factor NF-KB and the glucocorticoid receptor; Chest; 1995; 107 (3); 139; The American College of Chest Physicians.
H. Schacke et al; Mechanisms Involved in the Side Effects of Glucocorticoids; Pharmacology and Therapeutics; 2002; 96; 23-43; Elsevier.
H. Konig et al; Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo; The EMBO Journal; 1992; 11 (6); 2241-6.
P. Barnes et al; Anti-inflammatory actions of steroids: molecular mechanisms; TIPS Reviews; Dec. 1993; 14; 436-441; Elsevier.
A. Cato et al; Molecular Mechanisms of Anti-inflammatory Action of Glucocorticoids; BioEssays; 1998; 18 (5); 371-378.
R. Cumming et al; Use of Inhaled Corticosteroids and the Risk of Cataracts; The New England Journal of Medicine; Jul. 3, 1997; 337/1; 8-14.
C. Wong et al; Inhaled corticosteroid use and bone-mineral density in patients with asthma; The Lancet; Apr. 22, 2000; 355; 1399-1403.
D. B. Allen; Do intranasal corticosteroids affect childhood growth?; Allergy; 2000; 62; 15-18.
R. Pauwels et al; Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease who Continue Smoking; The New England Journal of Medicine; Jun. 24, 1999; 340/25; 1948-1953.
J. Faul et al; High Dose Inhaled Corticosteroids and Dose Dependent Loss of Diabetic Control; BMJ; Nov. 28, 1998; 317; 1491.
S. Luo et al; Ytterbium Triflate Catalyzed Reactions of Epoxide with Nitrogen Heterocycles Under Solvent-Free Condition; Synthetic Communications; 2003; 33/17; 2989-2994; Marcel Dekker Inc.
R. Andrews et al; Glucocorticoids and insulin resistance: old hormones, new targets; Clinical Science; Apr. 16, 1999; 96; 513-523.
M. Massa et al; Novel Heteroaryl Replacements of Aromatic 3-Tetrafluoroethoxy Substituents in Trifluoro-3-(tertiaryamino)-2-propanols as Potent Inhibitors of Cholesteryl Ester Transfer Protein; Bioorganic & Medicinal Chemistry Letters; 2001; 11; 1625-1628; Pergamon.
T. Lee et al; A Concise Asymmetric Route for the Synthesis of a Novel Class of Glucocorticoid Mimetics Containing a Trifluoromethyl-Substituted Alcohol; Bioorganic & Medicinal Chemistry Letters; 2006; 16; 654-657; Elsevier.
J. Song et al; Practical Stereoselective Synthesis of an alpha-Trifluoromethyl-alpha-alkyl Epoxide via a Diastereoselective Trifluoromethylation Reaction; Journal of Organic Chemistry; 2007; 72; 292-294; American Chemical Society.
Q. Cai et al; Preparation of N-Aryl Compounds by Amino Acid-Promoted Ullmann-Type Coupling Reactions; Synthesis; 2005; 3; 496-499.
A. Klapars et al; A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and the N-Arylation of Nitrogen Heterocycles; Journal of American Chemistry Society; 2001; 123; 7727-7729; American Chemcial Society.
J. Antilla et al; Copper-Diamine-Catalyzed N-Arylation of Pyrroles, Pyrazoles, Indazoles, Imidazoles, and Triazoles; Journal of Organic Chemistry; 2004; 69; 5578-5587; American Chemical Society.
A. Muci et al; Practical Palladium Catalysts for C-N and C-O Bond Formation; Topics of Current Chemistry; 2002; 219; 131-209; American Chemical Society.
M. Van Der Mey et al; Synthesis and Structure-Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids: A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents; Journal of Medicinal Chemistry; 2003; 46; 2008-2016; American Chemical Society.
S. Lulinski et al; Regiospecific Metalation of Oligobromobenzenes; Journal of Organic Chemistry; 2003; 68; 5384-5387; American Chemical Society.
F. Harden et al; Synthesis and Adenosine Receptor Affinity of a Series of Pyrazolo{3,4-d]pyrimidine Analogues of 1-Methylisoguanosine; Journal of Medicinal Chemistry; 1991; 34; 2892-2898; American Chemical Society.
J. Blair et al; Effect of Ring Fluorination on the Pharmacology of Hallucinogenic Tryptamines; Journal of Medicinal Chemistry; 2000; 43; 4701-4710; American Chemical Society.
Express-Pharma-Online (http://www.expresspharmaonline.com/20031023/edit/edit02.shtml).
U.S. Appl. No. 12/226,372, filed Oct. 16, 2008.
Biggadike Keith
Cooper Anthony William James
House David
McLay Iain McFarlane
Furman Theodore R.
Glaxo Group Limited
Loewe Sun Jae Y.
Stein-Fernandez Nora
LandOfFree
Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2624322